Zeneca's Casodex diarrhea incidence 50% lower than Eulexin in prostate cancer therapy -- ASCO.
Executive Summary
ZENECA CASODEX DIARRHEA INCIDENCE 50% LESS THAN EULEXIN in treatment of prostate cancer patients, according to results of a study reported by Nicholas Vogelzang, MD, University of Chicago, May 23 at the American Society of Clinical Oncology annual meeting in Los Angeles. The incidence of diarrhea was 10% in the Casodex (bicalutamide) group compared to 24% in the group treated with Schering-Plough's Eulexin (flutamide), leading to 43% fewer withdrawals from therapy in patients treated with Casodex.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth